Entities

Valencia biotechnology company developing targeted RNA medicines for genetic neuromuscular disorders. Its investigational lead compound ATX-01 is an anti-microRNA oligonucleotide targeting miR-23b, intended to restore muscleblind-like protein function and correct disrupted RNA splicing in myotonic dystrophy type 1. ATX-01 is being evaluated in the Phase I/IIa ArthemiR clinical trial. ARTHEx’s BOOST-ON platform combines selective oligonucleotides with tissue delivery designed to reach skeletal muscle, heart and brain, and supports additional research programmes in muscular, central nervous system and cardiac disease. The company originated from University of Valencia research.

Life sciences venture capital firm formerly known as Advent France Biotechnology, investing in and creating early-stage European biotechnology companies. It works with academic researchers and technology-transfer organisations to turn medical discoveries into startups, providing initial capital and operational support for company formation, recruitment, research strategy and subsequent financing. Its portfolio spans multiple therapeutic areas, including RNA medicines for neuromuscular disease and small-molecule approaches to neurodegeneration and neuroinflammation. The firm publishes teams in Paris, Barcelona and Montreal, with scientific, medical, investment and operating expertise.

Spanish venture capital firm founded by Javier García and Damià Tormo, investing in biotechnology therapeutics and the industrial technologies needed to develop and manufacture them. It backs and creates companies across drug discovery, clinical development, advanced therapies and biopharmaceutical production, combining scientific, medical and commercial expertise with active company building. Its life science funds balance therapeutic programmes with bioindustrial infrastructure and manufacturing capabilities. Its disclosed investments include ARTHEx Biotech’s RNA treatments for neuromuscular disease and companies developing gene therapies, diagnostics and advanced biological medicines.

Adviser to BEVC; life-science entrepreneur with experience in genomics, diagnostics and therapeutics.

Adviser to BEVC; UC Berkeley molecular biologist and biotechnology company founder.

Adviser to BEVC with experience in technology investing, semiconductors and entrepreneurship; co-founder of Congruent Ventures.

Adviser to BEVC; cellular neurobiologist and former UCSF and QB3 leader supporting scientific entrepreneurship.

Adviser to BEVC; UC Berkeley biochemist and Nobel laureate for CRISPR genome-editing research.

Adviser to BEVC; Stanford professor working on computational cancer genomics and biomedical data science.

Adviser to BEVC with expertise in computing, data science and artificial intelligence.

Adviser to BEVC; cleantech investor and materials-recycling entrepreneur.

Fractional Chief Financial Officer at BEVC with experience in venture capital finance and operations, including DCVC and Venrock.

Venture Partner at BEVC with venture investing and operating experience in climate, industrial and healthcare technology.

Founding Advisor to BEVC, UC Berkeley professor and biotechnology entrepreneur working on gene and stem-cell therapies.

Co-founder of BEVC with experience in venture investing and company creation, including Kleiner Perkins and GE Ventures.

Co-founder of BEVC; bioengineer with life-science investing and operating experience, including B Capital, Red Tree VC and InterVenn.

Investor at BEVC with a PhD in chemical engineering and experience in materials science, semiconductors and industrial chemistry.

BEVC is a Berkeley venture capital firm founded in 2023 by Rowan Chapman, Widya Mulyasasmita and Risa Stack. It invests in early-stage companies translating scientific discoveries into products across biology and health, artificial intelligence, energy, materials and deep technology. The firm works with founders in the UCSF, UC Berkeley and Bakar innovation ecosystems, combining investment capital with scientific, operating and commercialization support. Its publicly named portfolio includes AI-driven materials discovery, macrocyclic-peptide therapeutics, genetic medicines, critical-metal alternatives, brain-selective drugs and diagnostics. BEVC's operating team works alongside a network of scientific and industry advisers. It participated in Montara Therapeutics' March 2025 seed expansion.

General Partner at Two Bear Capital and Montara Therapeutics board member; Stanford-trained structural biologist with genomics, data science and software engineering experience.

Troy Wilson is listed by Montara Therapeutics as Chair of the Board.

Eric Karran is listed by Montara Therapeutics as Neuroscience Advisor.

Joseph Arena is listed by Montara Therapeutics as Regulatory Affairs Advisor.

John Burkhardt is listed by Montara Therapeutics as Toxicology Advisor.

Stevan Djuric is listed by Montara Therapeutics as Medicinal Chemistry Advisor.

Michael Keiser is listed by Montara Therapeutics as SAB Member.

Shawn Johnstone is listed by Montara Therapeutics as Synthetic Chemistry Advisor.

Miratul Muqit is listed by Montara Therapeutics as SAB Member.

Martin Kampmann is listed by Montara Therapeutics as Co-Scientific Founder & SAB Member.

Ziyang Zhang is listed by Montara Therapeutics as SAB Member.

Max Lebovitz is listed by Montara Therapeutics as Vice President, Business Operations.

Dirk Landgraf is listed by Montara Therapeutics as Chief Business Officer.

Rishi Rakhit is listed by Montara Therapeutics as Vice President, Pharmacology.

David Michelson is listed by Montara Therapeutics as Chief Medical Officer.

Zachary Hill is listed by Montara Therapeutics as Chief Technology Officer.

Nicholas T. Hertz is listed by Montara Therapeutics as Founder, President and Chief Executive Officer.

Montara Therapeutics is a San Francisco biotechnology company developing brain-selective medicines for neurological diseases. Its BrainOnly platform combines a brain-penetrant therapeutic with a peripheral blocker intended to limit drug activity outside the brain. The platform derives from UCSF research and an exclusive technology license. Its lead program, MTX-E1, combines the MT1110 peripheral blocker with everolimus for tuberous sclerosis complex-related epilepsy; additional research targets Parkinson's disease and other neurological conditions. As of September 2026, Montara was completing IND-enabling work and preparing for first-in-human studies. Its programs remain investigational. Founder and CEO Nicholas T. Hertz leads the company with Chief Medical Officer David Michelson, Chief Technology Officer Zachary Hill and Chief Business Officer Dirk Landgraf. The company raised an $8 million seed round in July 2024 and a $20 million seed expansion in March 2025, totaling $28 million in seed financing. The Michael J. Fox Foundation subsequently supported separate LRRK2 and mTOR Parkinson's research projects with non-dilutive grants.

Scandinavian venture capital firm investing in European and US private biotechnology companies developing novel medicines, especially programmes approaching or undergoing clinical testing. It finances development toward meaningful clinical results, takes board roles and reserves capital for follow-on rounds. Its partners combine biotechnology company-building, pharmaceutical development and venture investing experience. Its neuroscience portfolio includes Teitur Trophics’ neuroprotective peptides, alongside medicines for neuromuscular, immune, cardiovascular and other diseases. The Swedish manager is Sound Bioventures Management AB.

Aarhus University spin-out developing cyclic peptide medicines intended to preserve neurons and address the biological causes of neurodegenerative disease. Its lead candidate TT-P34 is a subcutaneous peptide designed to improve mitochondrial and lysosomal function, with Parkinson’s disease as its leading clinical indication and additional research into Huntington’s disease and frontotemporal dementia. The company reported Phase I safety, tolerability and central nervous system exposure results in September 2026 and plans further clinical development. Its pipeline also explores hearing loss and Duchenne muscular dystrophy. The treatments are investigational.

SV Health Investors venture partner, Autifony Therapeutics co-founder and independent chair of Teitur Trophics; neuroscientist specializing in ion channels and neuropsychiatric drug discovery.

Operations Manager at KdT Ventures, US Air Force veteran and venture/startup operations professional.

Head of Talent at KdT Ventures, with a PhD in molecular biophysics and experience in life-science executive recruiting.

Head of Operations at KdT Ventures with experience in administration, flight operations and team management.

Managing Partner at KdT Ventures and former startup attorney.

Associate at KdT Ventures with a PhD in pharmacology and research experience in receptor signaling and cellular trafficking.

Principal at KdT Ventures and physician-scientist with experience in molecular imaging, translational oncology and technology commercialization.

Mary Zhucui is listed by SOSV as Risk Controller.

Jenny Zhou is listed by SOSV as Sourcing Assistant.

Qiyu Wu is listed by SOSV as Operations Director.

Vitaly Vyazovsky is listed by SOSV as Creative Director.

Avra van der Zee is listed by SOSV as General Partner. Board positions Avra has board experience in various early-stage companies and currently serves as Chairperson of the Board at Made of Air.   Career 2023 – Chairperson of the Board, Made of Air 2022 – 2023       Board Director, Made of Air 2021 –   Chief Operating Officer, Elemental Excelerator   2020 – Strategic Advisor & Board Director, Various early-stage companies 2020 – 2021        VP, Strategy and Policy, Superpedestrian 2018 – 2020        Director, Global Market Entry, Uber 2014 – 2018         General Counsel and Chief Strategy Officer, JUMP Bikes 2009 – 2014        General Counsel, Trespa North America 2007 – 2009       Litigation Associate, Paul, Weiss, Rifkind, Wharton & Garrison LLP Education Avra holds a BA in History and Literature from Harvard University and a JD from Georgetown University Law Center.

Joshua Torrey is listed by SOSV as IT Manager.

Tushar Tomar is listed by SOSV as Workshop Manager.

Yash Suryawansh is listed by SOSV as Mechatronics Engineer.

Sabriya Stukes is listed by SOSV as Partner, SOSV NY.

Tyler Shi is listed by SOSV as Mechanical Engineer.

Bethany Watson is listed by SOSV as Program Manager, SOSV NY.

Catherine Seo is listed by SOSV as Corporate Investor Relations & Analyst, SOSV SF / Associate, SOSV SF.

Susan Schofer is listed by SOSV as Partner & Chief Science Officer.

Wasim Salih is listed by SOSV as Industrial Designer.

Anuraj Rawat is listed by SOSV as Investment Analyst, HAX.

Marc Rose is listed by SOSV as Engineer, HAX.

Charles Peter is listed by SOSV as Director of Mechanical Engineering.

Joe Oliveira is listed by SOSV as Workshop Manager, HAX.

Rian O’Neill is listed by SOSV as Fund Analyst.

Edwina O’Brien is listed by SOSV as Assistant Accountant, SOSV.

Maria O’Brien is listed by SOSV as Senior Operating Partner.

Melanie O’Connor is listed by SOSV as Investor Relations Associate.

John O’Brien is listed by SOSV as Global Director of IT.

Mark Nolan is listed by SOSV as Finance Manager.

Donnacha Murphy is listed by SOSV as Operations Analyst.

Finance Director at SOSV in Cork, overseeing financial, compliance and tax affairs and supporting portfolio companies with financial planning.

Siobhán Murphy is listed by SOSV as General Counsel.

Michael Moon is listed by SOSV as Director of Electronic Engineering.

Stephen McCann is listed by SOSV as General Partner & Chief Financial Officer, SOSV.

Sandra Manning is listed by SOSV as Head of HR.

Carrie Mandy is listed by SOSV as Investment Analyst.

Cambridge neurotechnology startup developing a wearable device for non-invasive brain stimulation using low-intensity focused ultrasound. Its prototype neuromodulation system combines hardware, stimulation protocols and neuroscience research, with intended future applications in clinical treatment, neurological and mental-health disorders, and cognitive wellbeing. The company is developing its early prototype toward clinical validation and exploring complementary stimulation and closed-loop approaches. Its research interests include depression, addiction, OCD, pain and cognitive function; these are development goals rather than approved indications.

Norwegian healthcare investment company founded in November 2018 and based in Stavanger, operating within the family-owned TD Veen investment group. P53 invests long-term capital in science-based healthcare companies developing treatments and technologies. It supports commercialization and company development through sector expertise, board participation and active work with management and co-investors. Its team combines medical and cancer-research backgrounds with investment and financial-market experience, supporting businesses from startup through later clinical development.

Cambridge biotechnology company developing three small-molecule drug candidates for obsessive-compulsive disorder. The programmes target distinct neurological mechanisms involving glutamate/GABA balance, AMPA receptor signalling and dopamine modulation, seeking more effective and faster-acting treatment options. Serenatis pairs its therapeutic work with precision biomarkers and computational approaches intended to identify relevant patient biology and guide treatment development. It is advancing preclinical work toward clinical trials, with AI engineering, clinical psychiatry and neuroscience expertise supporting its research.

Former private-equity M&A lawyer and corporate legal consultant, with experience advising healthcare startups on transactions, intellectual property and data privacy. Leads Mendea Technologies.

Executive Assistant supporting SOSV's Managing General Partner; previously worked in music education and human resources.

David Cavalla has 35 years experience in various senior scientific and commercial roles within the pharmaceutical industry. Previously he was founder and CEO of Arachnova Ltd, a company focused on therapeutic switching; previous affiliations included Glaxo Group Research Ltd and Napp Research Centre.

Hannah is Communications Officer at Serenatis Bio, where she works across scientific communication, investor outreach, and research analysis in support of the company’s mission to develop novel therapies for OCD. With an academic background in mathematics, physics, and history, alongside experience in both qualitative and quantitative research, she brings a strong analytical and interdisciplinary perspective to her work. Being passionate about science communication and making complex ideas accessible, she contributes to Serenatis Bio’s social media, website, investor engagement, and scientific literature reviews.

Prof Jon Grant is Professor of Psychiatry at University of Chicago and director of a clinic and research lab on addictive, compulsive and impulsive disorders.

After graduating from Loughborough University in 1997, Julia joined PriceWaterhouseCoopers and qualified as a Chartered Accountant in 2001. For the last 15 years, as the founder and Managing Director of Archangel Accounting Ltd, Julia has provided tailor-made services to many companies, including IPO and fundraising support. Julia Jones provides fractional finance leadership to TRIMTECH. A Loughborough graduate and chartered accountant trained at PwC, she founded Archangel Accounting and supports biotechnology companies with finance operations, fundraising and IPO preparation. This fractional role is distinct from any other retained company finance affiliation.

Nick Sireau is an OCD advocate and also co-founder and Chair of Orchard OCD, a medical charity that funds academic research into OCD. Nick runs a support group for people with severe OCD where he lives in Cambridge, UK.

Reet is an AI Engineer at Serenatis Bio, where she applies artificial intelligence and computational methods to accelerate and optimise the discovery of novel therapies for OCD. With formal training in biotechnology, bioinformatics, and computational biomedical engineering, she holds research experience in AI-driven drug discovery and healthcare technologies. Reet is also a named author on several scientific publications. Together, this experience contributes to Serenatis Bio’s precision approach to developing more targeted therapies for OCD.

Dr Susanne Stuffers is CEO and Founding Partner of p53. She holds an M.D. degree from the Erasmus University Rotterdam, Netherlands, and a Ph.D. degree in cancer biomedicine from the Norwegian Radiumhospital. She gained broad experience in healthcare and life sciences, covering the sector from several angles. Susanne was a management consultant in health care (public and private) and life sciences at EY, served in medical and commercial roles in the pharmaceutical industry (Novartis), and has clinical practice as a resident in oncology. She worked with Arctic Securities as an equity analyst covering the healthcare sector, before joining forces with T.D. Veen to co-found and lead p53.

Woojung Lee is listed by SOSV as Associate.

Manvendra Kumar is listed by SOSV as Senior Mechanical Engineer.

Ian Koss is listed by SOSV as Lead Software Developer.

Kelly Kirkpatrick is listed by SOSV as Partner & Director of Investor Relations.

Ji Ke is listed by SOSV as Partner & CTO, HAX.

Daniel Kavanagh is listed by SOSV as Finance Manager.

Meghan Hind is listed by SOSV as Data & Business Analyst.

General Partner at SOSV SF and physician-entrepreneur with more than 25 years of experience leading life-science startups.

Brit Harley is listed by SOSV as Office Manager.

Arvind Gupta is listed by SOSV as Venture Advisor.

Andrew Gollach is listed by SOSV as Partner.

Bella Giordano is listed by SOSV as Administrative Assistant to SOSV’s Managing General Partner.

Alex Firestine is listed by SOSV as Analyst.

William Farah is listed by SOSV as Legal Counsel.

Sophie Dorgan is listed by SOSV as Legal Operations Analyst.

Pia Doran is listed by SOSV as Office Manager.

Communications and marketing advisor at SOSV, previously its senior operating partner.

Cassandra De Jesus is listed by SOSV as Facilities Coordinator.

Jackie Della Torre is listed by SOSV as Events & Community Manager.

Kira Colburn is listed by SOSV as Director of Communications.

Tina Chen is listed by SOSV as Operations Assistant.

Sierra Brooks is listed by SOSV as Senior Scientist & Analyst, IndieBio / Associate, IndieBio.

Po Bronson is listed by SOSV as General Partner & Managing Director, SOSV SF.

Hugh Bowen is listed by SOSV as Associate, SOSV / Associate, SOSV SF.

Madeline Behr is listed by SOSV as Principal, Investor Relations & Capital Formation, SOSV.

Parsa Amiri is listed by SOSV as Investment Analyst.

Norm Amandi is listed by SOSV as Video Content Director.

Selin Altinok is listed by SOSV as Investment Analyst.

Ghaith Alghamdi is listed by SOSV as Principal.

Toshi Akashige is listed by SOSV as Laboratory & Safety Manager.

Supriya Agarwal is listed by SOSV as Director of Marketing, Data & AI.

UK biotechnology and medical-device company developing an implanted treatment for glioblastoma, an aggressive brain cancer. Its ALIGHT device is designed to be placed in the surgical cavity after tumour removal and act as a decoy nerve, attracting and directing invasive cancer cells into a controlled location instead of letting them spread through healthy brain tissue. The company engineers fibre materials around cancer-cell migration, progressing from laboratory proof of concept toward device prototyping and preclinical validation. Co-founders Peter Bannister and Davide Danovi bring medical-device, imaging and cancer-biology expertise.

London medical-technology company developing a handheld surgical guidance system for brain-tumour operations. Its probe uses Raman spectroscopy and machine learning to classify molecular tissue signatures in real time, helping surgeons distinguish tumour tissue from healthy brain and assess tumour grade. The system is designed to provide visual and auditory guidance during resection without contacting or damaging the sampled tissue. Neurolase is developing its hardware and AI models toward further clinical validation and regulatory approval. Co-founders Monika Kott and consultant neurosurgeon Babar Vaqas combine commercial healthcare experience with clinical invention.

UK venture-capital manager specializing in seed and early-stage science and technology companies, with a focus on businesses in and around Oxford. It manages a combined SEIS/EIS startup investment programme and a knowledge-intensive EIS programme, supporting initial company formation and later funding of selected portfolio businesses. Its published typical investments are up to £150,000 of seed capital and up to £300,000 of follow-on capital. The team assesses scientific technology, helps founders develop business models and pricing, and connects companies with further investors through the Wider Oxford Technology Angel Network. Its portfolio spans medical devices, AI, advanced materials, biotechnology and other technical fields.

UK software company building a shared digital platform for neurodevelopmental assessments and care. Its initial provider tools streamline adult ADHD assessments through a patient app for pre-assessment information, structured clinician workflows, AI-assisted documentation and draft assessment reports and letters. Clinicians review, edit and approve the output. The platform organizes patient-supplied information and clinician-entered notes to reduce administration and improve communication across care pathways. Its leadership combines clinical neurodiversity expertise, data science and experience living with ADHD.

Asher joined Oxford Technology in 2024. He has a degree in Linguistics from the University of Oxford and experience performing numerical calculations in a range of programming languages.

Consultant neurosurgeon and inventor of Neurolase’s surgical guidance system. Trained at Oxford, Cambridge, Imperial College London and UCL; leads technology development and clinical implementation.

Bijan founded and exited InCa, a FGPA Prototyping company seeded by Oxford Technology back in the 1980s. He then spent two decades with Synopsys, helping grow it from 300 to 13,000 employees. Bijan missed working with start-ups, however, and now consults our companies on the US market. He is also currently the CEO of Mach42.

Biomedical researcher and clinician working on glioblastoma biology and cancer-cell migration; scientific co-founder of Migration Biotherapeutics.

Former NHS consultant with experience leading health-system reforms and advocating for inclusive neurodevelopmental care.

Lucius raised his first science and technology seed fund in 1983, after founding and exiting his first business.  He has been investing in science startups ever since. He has a degree in Economics and Engineering from Oxford and an MBA from Harvard Business School. In 2003 he was awarded an OBE for services to business.

Mateusz joined Oxford Technology in 2022. He has a civil, structural, and mechanical engineering background and obtained a DPhil (PhD) degree in advanced shape-shifting mechanisms from the University of Oxford. At Oxford, Mateusz worked with and advised technology startups, mainly in robotics, aerospace, and agriculture.

Healthcare entrepreneur with experience in M&A and healthcare consulting. Leads Neurolase’s product development, partnerships, investor relations and commercial expansion.

Medical-device entrepreneur with expertise in imaging and regulatory strategy; commercial co-founder of Migration Biotherapeutics.

Data scientist developing neuro-inclusive software and assessment tools at ThinkDivergent.

AI biotechnology company developing a computational brain-discovery platform for neurological drug research. It uses blood-sample data to infer cell-specific molecular and epigenetic features of the brain, aiming to identify biomarkers, disease mechanisms and drug targets without directly sampling brain tissue. Starting with Alzheimer’s disease, Epiome seeks to help pharmaceutical researchers stratify clinical trials and develop treatments that slow or prevent neurodegeneration. It combines machine learning with functional genomics and cell biology, pursuing both discovery services for pharmaceutical partners and an internal therapeutic pipeline. Its published founders are Rowan Rimington and Jessie Li.

Cambridge neuroscience biotechnology spinout developing small-molecule medicines that protect astrocyte networks in the brain. Its preclinical pipeline seeks to slow Parkinson’s disease progression and address both motor and non-motor symptoms, with potential applications in other neurological disorders. The company targets several molecular mechanisms in astrocytes, a type of brain cell involved in maintaining neuronal function. It uses brain-penetrant compounds and translational drug discovery to develop disease-modifying treatments, rather than only symptomatic therapies.

UK pre-seed venture investor and venture builder operating as Zinc, with investment management conducted by Zinc Investment Management LLP. It backs science-led companies addressing health and environmental challenges, including neuroscience, AI, biotechnology, medical devices, advanced materials and clean energy. Zinc invests from the earliest stages of company creation and combines first-cheque funding with scientific assessment, commercial development and founder support. Its Science-for-Impact strategy helps researchers and entrepreneurs turn scientific discoveries into scalable businesses. The manager’s published leadership includes co-founders Paul Kirby and Ella Goldner as managing partners, and co-founder Saul Klein as a board member.

Claire is a qualified accountant with extensive experience building and scaling functions across startups and venture funds. Before joining Zinc, she held senior roles at Entrepreneur First and a range of high-growth technology businesses.

Prof Claire Thompson, formulation expert and entrepreneur, supporting drug development through multiple milestones and ensuring translational viability.

David is a deeptech investor, advisor, and entrepreneur with extensive global experience. As CEO of Sonosine and co-founder of Spectroma, he has led the development of pioneering medical technologies. He has worked extensively with private equity firms and venture capital investors globally, supporting entrepreneurs, scientific founders, and management teams with strategic insight, operational expertise, and mentorship. David holds an MSc in Industrial Engineering with a specialisation in Mechanical Engineering.

Eleanor joined Zinc in Oct 2019 to launch the new Zinc Academy. Most recently Eleanor was Director of the Good Lab, a radical innovation collaboration of 12 of the UK’s largest charities, looking to transform how they raise funds through venturing. Eleanor started her career as an anthropologist and documentary filmmaker, before landing in the world of start-ups in 2006, founding a technology company, LikeCube, which was acquired by Oakley Capital Private Equity and the Time Out Group, where she stayed for 5 years as Global Innovation Director.

Ella is a former Strategy Director at IPG Mediabrands, one of the world’s largest media agencies, working with global leading brands. She is the Co-Founder of NewCo UK, which connects the most successful large corporates with the most innovative start-ups in the UK. Ella started her career as an engineer in Tel Aviv’s hi tech aerospace industry, before becoming a consultant to tech firms.

Emilie has nearly a decade of experience in building and investing in university spinouts, as part of the Investment Committee at Parkwalk Advisors and previously at Oxford University Innovation, where she worked both in Investments and leading the Startup Incubator, managing over 80 ventures from inception to exit. She moved into technology transfer after 14 years as a research scientist, directing pioneering experiments in systems neuroscience in Oxford, Bordeaux and Hamburg. Emilie holds a PhD in Neuroscience from the University of Hamburg and an MBA from Warwick Business School, specialising in Strategy and Finance.

Dr John Skidmore, Chief Scientific Officer, Alborada Drug Discovery Institute at Cambridge, offers advice in medicinal chemistry and biodistribution assessments of pharmaceuticals.

Dr Brotchie, Parkinson’s Adviser, a co-founder and Chairman of Atuka Inc specialising in advanced preclinical Parkison’s models and translatability of disease mechanisms from models to clinic. He has led translational research that supported the advancement of 14 drug candidates to clinical studies.

Kate has spent the past decade working with founders of early stage B2B startups, helping them to find product market fit and to scale. Her key areas of expertise include marketing and go-to-market strategies, building thriving B2B communities, and the people & culture aspects of team building.

Dr Lewis Pennicott is a medicinal chemist with over 20 years’ experience across biotech, academic and CRO environments. He has led small-molecule programmes from hit discovery through to lead optimisation and candidate selection. Lewis brings deep expertise in complex synthesis, SAR-driven design and collaborative drug discovery to support the development of novel therapies for neurological disease.

Lily started her career at Ernst & Young (‘EY’), where she qualified as an accountant. She gained a wide range of experience working across many different sectors, including working on advisory projects with sporting clients such as World Rugby, Rugby Football Union, as well as working in M&A structuring with large private equity houses.

Prof Tansey, Parkinson’s Adviser, James A. Caplin MD, Chair in Alzheimer’s Disease, Professor of Neurology, Director of Neuroimmunology Research & Executive Associate Director of Education at Stark Neuroscience Research Institute, Indiana University School of Medicine. She is an expert in the inflammatory aspects driving Parkinson’s disease.

Prof Grazia Spillantini, Parkinson’s Adviser and Professor of Molecular Neurology at University of Cambridge, is a pioneer of alpha-synuclein research that described how abnormal protein misfolding contributes to cell dysfunction and demise in Parkinson’s.

Mark is a passionate and purpose-driven leader in life sciences and health tech, with three decades of experience building and scaling organisations that use data and innovation to improve lives. A founder, investor, and advisor, he has led businesses with revenues exceeding £1BN, raised more than £250M in capital, and delivered multiple successful exits. Known for his collaborative approach and ability to unite industry, academia, and the NHS, Mark has shaped partnerships and platforms that advance real-world data, genomics, and digital health globally. Guided by empathy, creativity, and commercial discipline, he is committed to developing purpose-led ventures and the next generation of health innovators.

Martin is a Chartered Chemical Engineer with extensive experience at bp, recognised for a passion for commercialising technology and a talent for turning ideas into action through a collaborative approach. His career reflects a strong track record in corporate venturing, digital strategy development, and technology incubation, consistently delivering results through influence.

Martyn Postle is a Senior Director who has worked in and for the life science sector for over 40 years with a network in Europe, USA, Asia, and the Middle East. He has a track record of building successful businesses from the ground up.

Dr Nat Hastings has over 10 years of experience in clinical research and bioengineering at the University of Cambridge with specialist knowledge in astrocytic network biology and Parkinson’s disease. Grant management and equity fundraise.

Natalie has a PhD in medical science (ophthalmology and inflammation), then biotechnology and healthtech startup operator across Canada, UK, EU and globally, then venture building and investing, culminating in ~15 years of 360 healthcare experience. She can be found sometimes lecturing, advising and consulting for cool and impactful organisations like WHO, European Innovation Council, Hult Prize, and UK Parliament.

Paul is a former partner at KPMG and the global head of public services and government. In his career, he has been Head of the Number 10 Policy Unit, as well as working in the media, education, transport and urban regeneration sectors. Paul is a Visiting Professor at the London School of Economics & Political Science and was a Director of Bethnal Green Ventures and a Non-Executive Director of the Cabinet Office.

Ro Gardner, Operations Adviser, expert in logistics, management, governance, business administration, and communications with a specific focus on companies at earlier stages of growth.

Dr Shaun McNulty is a biochemist with over 25 years’ experience leading drug discovery, including 12 years as a biotechnology CSO. He has led programmes from hit discovery through candidate selection and clinical development. Shaun brings deep expertise in preclinical development, translational strategy and building high-performing global R&D units to support the development of novel therapies for neurological disease.

Dr Shawn Manning’s career spans >30 years in life sciences overseeing multiple aspects of corporate strategy planning, governance, and operations management. He brings experience in financial planning and modelling with a focus on medical research.

Stephen Grant, Chairman, executive level international leader with experience in pharma, biotech, and life science, overseeing all stages of business growth from early fundraising to successful exit strategies.

Toby Wilson Waterworth, Business Adviser, an internationally experienced Board member and senior executive with broad experience of developing biopharmaceutical and healthcare companies as well as navigating regulatory pathways to bring drugs to market, with a track record of previous success.

Boutique investment bank advising companies and investors across brain health and neuroscience. It supports capital raising from Series A through pre-IPO, mergers and acquisitions, strategic partnerships and licensing. Its coverage includes CNS therapeutics, neurotechnology and brain-computer interfaces, diagnostics and biomarkers, digital neurohealth, AI-enabled drug development, specialist research organizations and clinical-trial infrastructure. Partners lead selected engagements and provide transaction advice and sector-specific diligence.

Leads neuroscience and mental-health research and diligence at Dragonfly 44 Capital. Previously worked in neuroscience equity research at H.C. Wainwright, M&A at atai Life Sciences and clinical research at Memorial Sloan Kettering Cancer Center. Holds a master’s degree in bioengineering from Cornell University.

Early-stage venture investor focused on neuroscience, neurotechnology and brain health. D44 backs brain treatments, devices and diagnostics, and AI and data platforms, including brain-data models, brain-inspired computing and AI-assisted drug research. It combines clinical and scientific diligence with assessment of practical trials, regulatory pathways and commercial adoption, and supports founders as they build evidence for their products. Its investment focus is global with an emphasis on the United States. Dragonfly 44 Capital announced the launch of its D44 Ventures fund in June 2025.

Neuroscience venture investor and founder and managing partner of Dragonfly 44 Capital, a brain-health investment bank. Holds a Master of Business and Science in Biotechnology and Genomics from Rutgers University and a bachelor’s degree in biological sciences.

1540 Ventures is an early-stage investment firm with listed offices in New York and Fremont, California. It invests from pre-seed through Series A in medical devices and technology, life science tools, in-vitro diagnostics and women's health. Its stated areas of interest include TechBio at the intersection of digital biology and medicine, intelligent devices and data integration, software as a medical device, women's digital health, and digital manufacturing software and services. The firm works with corporate strategic investors, development partners and incubators, and seeks portfolio companies with identified milestones and interest from potential corporate or financial partners. Its official website identifies Rob King as Partner and Chief Investment Officer. In September 2025, AiM Medical Robotics named 1540 Ventures as co-lead of its $8.1 million Series A alongside IQ Capital, supporting MRI-compatible neurosurgical robotics for brain disorders and cancer. The firm does not disclose a complete portfolio directory or fund size on its current public website.

SV Health Investors biotechnology vice president with immunology research and company formation experience; previously led business development and strategy at Xilio Therapeutics and worked at L.E.K. Consulting.

Andy Richards is listed by Cambridge Innovation Capital as advisory panel member. Life-sciences entrepreneur involved in Chiroscience and healthcare boards; his published background includes neuroscience and digital mental-health businesses. This affiliation follows CIC’s published directory; other career appointments are scoped to its biography and do not imply personal investment tickets. Andy Richards is publicly named by Cambridge Angels in its selected individual-member directory. Membership is an angel-network affiliation: individual investment choices are independent, and membership alone does not prove personal investment in any portfolio company.

Jonathan Tobin is partner at Brandon Capital. He joined the London investment team in2021 after Arix Bioscience and Touchstone Innovations. His educational background spans Oxford biology, UCL molecular medicine and an Imperial MBA, alongside Cancer Research UK postdoctoral work. His established Cancer Research Horizons affiliations are preserved. These career statements come from the firm’s own biography; other company affiliations do not establish personal cash investments, and exact appointment days are not inferred.

Cancer Research Horizons Ventures is the specialist venture creation and investment team within Cancer Research Horizons, Cancer Research UK's innovation and commercialization organization. The team manages an evergreen philanthropic Seed Fund, providing pre-seed, seed and follow-on support for oncology ventures in therapeutics, diagnostics, medical devices, and data-driven or AI solutions. Its 2025/26 impact report states that typical investments range from £50,000 to £1.5 million, and that the Seed Fund has reached its £30 million capitalization target. The fund launched in June 2022 with a rolling £15 million five-year Cancer Research UK commitment; further philanthropic support expanded the same fund. Returns are reinvested in the fund and cancer research. The current public Ventures roster comprises seven staff and two investors-in-residence, led by Associate Director Phil Masterson, with an independent seven-member investment committee chaired by Vishal Gulati. The fund reports £14.33 million committed across 43 investments in 33 start-ups; the broader parent start-up portfolio also includes businesses supported through licensing rather than investment. The Ventures Seed Fund participated in AiM Medical Robotics' $8.1 million Series A to support development and validation of MRI-compatible neurosurgical robotics in an oncology setting. Other reported brain-cancer portfolio work includes Trogenix. This profile represents the Ventures investment team and uses the official shared Cancer Research Horizons branding.

Leads U.S. investments; joined IQT in 2017.

Former Arnold & Porter Kaye Scholer partner overseeing IQT legal affairs.

Former Point72 Private Investments managing partner and U.S. Marine.

Directs overseas investments; previously led IQT’s portfolio success function.

Former IQT Chief People Officer and Council on Foundations COO.

Marketing and operations leader who joined IQT in 2012.

Joined IQT in 2003; previously its EVP and CFO.

Biochemistry and molecular-biophysics researcher; previously a Fluidigm senior scientist.

Former InterWest general partner; joined IQT in 2006.

Electrical-engineering researcher and former Booz Allen Hamilton technology adviser.

Named member of Wavemaker 360’s Portfolio Support Alliance, a selected external LP-support network providing deal flow, diligence and commercial assistance. Published outside affiliation: New York Angels. This is a qualified support/advisory relationship, not a claim of employment, general partnership or personal cash participation. Exact NewYorkAngels currentJune2026newsletter explicitlyidentifies TomHirschfeldAiMdeal lead, corroborating existingAiMboardobserveridentity.

John Rolston is listed on RebrAIn’s published scientific/medical advisory board, with affiliation Brigham and Women’s Hospital, Boston; also Harvard neurosurgeon and AiM Medical Robotics adviser.

Materials-science and quantum-technology researcher who co-founded Quantum Boost with Kacper Kielak. The company identified him as CEO in its 2023 publications.

Machine-learning engineer and co-founder of Quantum Boost, identified as CTO in its 2023 publications. His public professional profile now lists Magic; a current CTO role at Quantum Boost is not inferred.

Aerospace and communications industry professional with managing-director experience, listed on Kurs Orbital’s team page.

Rendezvous and proximity operations specialist with experience in the KURS docking systems. Also listed as Vadim Vasiliev on the company team page; appointed to CONFERS’ board in 2025.

Space entrepreneur and former chairman of the State Space Agency of Ukraine. Co-founder and chief executive of Kurs Orbital.

The Sontag Innovation Fund is a venture philanthropy subsidiary of The Sontag Foundation, established in 2021 to advance technologies for the diagnosis, treatment, prevention and cure of brain cancer. It supports early-stage, high-risk therapeutics, diagnostics, medical devices and other technologies, using loans and equity investments in both for-profit and nonprofit organizations. It seeks to recover principal to recycle capital toward its charitable mission. Managing Director Scott Davis, Ph.D., manages venture philanthropy and impact investments; Life Sciences Associate Justin Siemann, Ph.D., conducts scientific due diligence, market analysis, financial modeling and portfolio management. Its public directory lists eleven current companies and one exit: Modifi Bio, acquired by Merck in October 2024. Current holdings include Myosin Therapeutics, AiM Medical Robotics, Alpheus Medical, Altido Therapeutics, Cordance Medical, EnClear Therapies, FYR Bio, Kiyatec, MimiVax, TippingPoint Biosciences and Telo Therapeutics. Myosin explicitly named the fund as a participant in its second seed financing announced in February 2025. The 2021 fund launch is distinct from the parent foundation's establishment in 2002. The profile uses the official shared foundation branding displayed on the fund's website.

MintPharma Capital is a biotechnology and life sciences investment firm led by co-founders and partners Robert G. Finizio and David Adams. It targets very late preclinical and early clinical biotech and pharmaceutical companies, typically investing $2 million to $5 million in seed or Series A financings and often acting as a lead investor. Its public team also includes General Counsel Marlan Walker, CFO adviser Brian Mooney and Louie Adams in investor relations and operations. The current portfolio lists nine businesses, including neuroscience companies Myosin Therapeutics, PleoPharma and Astrocyte Pharmaceuticals, alongside oncology, genetic diagnostics and drug-delivery companies. Astrocyte named MintPharma Capital as a new investor in its $9.5 million Series B announced in September 2026. Mint12 LLC describes a strategic partnership with MintPharma Capital; the relationship does not by itself establish that the firms, or the historically named investor Mint12 Pharma LLC, are the same legal entity.

Defense and intelligence professional with experience at SAIC, Sandia National Labs and Raytheon and as a senior national security adviser to the US Congress. Published by Acequia as Venture Partner, Intel & Defense; identity kept separate from the same-name IQT life-sciences investor.

Venture capital investor since 1996 who runs Chalfen Ventures as a solo investor backing early-stage European software founders.

Former chief information officer at General Atlantic and Carlyle, named as an angel investor in Tracelight’s August 2025 seed financing.

Former Jane Street engineer and co-founder of Tracelight.

Former founding engineer at 11x and co-founder of Tracelight.

Former McKinsey consultant and Entrepreneur First team lead. Co-founded Tracelight in 2024.

Myosin Therapeutics is a clinical-stage biotechnology company in Jupiter, Florida, developing small molecules that target molecular nanomotor proteins for oncology and central nervous system conditions. Founded in 2020 by Courtney A. Miller, Patrick R. Griffin and Theodore Kamenecka, it is a spinout of the institute now known as the Herbert Wertheim UF Scripps Institute. Its lead oncology program, MT-125, targets non-muscle myosin II and is being evaluated in the Phase 1/2 STAR-GBM trial for newly diagnosed glioblastoma; the company reported first-patient dosing in May 2026. MT-110 is being developed for methamphetamine use disorder. These therapies remain investigational. Founder, Chairperson and CEO Courtney Miller leads eleven publicly listed leadership members and five medical and scientific advisers. The current site lists Griffin and Kamenecka as founders, directors and CSOs. Myosin's first seed financing began in December 2022 and reached $2,999,986 in the March 2023 SEC amendment; its second seed round, announced February 2025, raised over $3 million. DeepWork Capital participated in both, and Mayo Clinic Ventures joined the second. NIH records identify four company grant project series with about $12.083 million in appropriations through fiscal 2026, including ongoing drug-development and clinical research programs. A separate $2 million Florida Cancer Innovation Fund award was announced in March 2026 for the STAR-GBM study. Research grants, clinical designations and conference participation are kept separate from equity financing and drug approval.

Co-founder and former CTO of Applica, where he developed multimodal document-understanding models. Leads engineering and architecture of Ingenix’s Biological Reasoning Engine.

Former EMEA lead for Healthcare & Life Sciences Startups at Amazon Web Services and co-founder of AION Labs. Leads commercial strategy, partnerships and Ingenix’s Qualified Access Program.

Co-founder and former CEO of Applica, acquired by Snowflake in 2022. Leads Ingenix’s overall direction, strategy and scientific vision.

Computational biology researcher formerly a senior scientist at InSilico Medicine and director of AI and Data Science at Ardigen. Leads Ingenix’s scientific work at the intersection of AI and biology.

Computer science PhD and former senior engineering manager at Snowflake following its acquisition of Applica. Leads AI research and core architecture development at Ingenix.

Vice President and Global Head of R&D Oncology at Servier and former Head of Cell Therapy and Early Translational Oncology at Takeda. Advises Ingenix on translational and clinical strategy in oncology.

Raul G. Nogueira is named on Anaconda Biomed’s current public scientific advisory board. The issuer describes the clinician’s external clinical affiliation as Endowed Professor & Division Chief of Cerebrovascular Medicine, and Professor of Neurology and Neurosurgery, University of Pittsburgh. Director, UPMC Stroke Institute. Past President of the Society of Vascular and Interventional Neurology and the former Editor-In-Chief of the Interventional Neurology journal.. This is an advisory relationship rather than company employment.

Astrocyte Pharmaceuticals is a clinical-stage biotechnology company in Groton, Connecticut, developing investigational cerebroprotective therapies for traumatic brain injury, concussion, stroke and other neurological conditions. Its lead small molecule, AST-004, is designed to enhance astrocyte energy metabolism through adenosine A1/A3 receptor activation. The company reported completion of enrollment in its Phase 2 STARFAST sports-related concussion trial in September 2026; results and therapeutic benefit remain under investigation. It is also researching oral formulations and additional neurological indications. Co-Founder and CEO William S. Korinek leads a public team of six management members, seven board members and seven clinical and scientific advisers, with overlap across these groups. Co-Founder James D. Lechleiter remains an adviser. Its 2017 seed financing expanded from approximately $1.36 million to over $2.4 million at final closing, followed by a $6 million Series A announced in May 2021, a pre-Series B bridge of over $6 million in August 2023 and a $9.5 million Series B led by DeepWork Capital in September 2026. The company's reported $40 million invested to date includes grants and is not another equity round. NIH records identify four grant project series with approximately $7.365 million in awarded appropriations through fiscal 2026, kept separate from private financing.

Healthcare technology company developing AI software for pharmaceutical commercialization. Its Pathwai platform analyzes demographic information to help pharmaceutical manufacturers, advertising agencies and publishers understand and reach relevant patient, healthcare-professional and caregiver audiences without relying on protected health information. It combines audience exploration, AI-assisted audience creation, media activation and outcome measurement in one workflow. BranchLab aims to replace fragmented research, marketing and measurement processes with predictive models and commercial intelligence. Its work supports healthcare marketing and commercialization decisions rather than providing medical care directly.

Austin, Texas early-stage venture capital firm founded in 2019 that invests at the intersection of healthcare delivery, consumer health and technology. It backs companies improving access to care, enabling proactive health management, extending healthspan and making healthcare systems more connected and efficient. Its portfolio includes AI-enabled care delivery and pharmaceutical commercialization, clinical intelligence, diagnostic technologies, fertility care and wearable health devices. The firm combines investment capital with support for marketing, commercialization, talent and executive leadership, drawing on its partners’ experience across health, wellness, sports and healthcare services.

Serves as Board Member at Paradigm Health, according to its current team directory.

Ben Patz is co-founder and general managing partner of DeepWork Capital, according to his own manager biography. He founded ColemanTechnologies, sold to Presidio in2009, and subsequently served as Presidio COO through2013. His engineering research included fuzzy logic and neural-network control systems, and he led UCF’s DARPA Urban Challenge team; he holds electrical-engineering degrees from UCF and Rensselaer. Circuitry.ai announced in its October1,2025 seed release that he would join its board. That announced appointment is source-qualified rather than asserted as independently confirmed current2026 board service. His existing authentic manager photograph and all external roles are preserved.

Biotechnology company developing precision medicines for neuropsychiatric disorders, with initial preclinical programs for major depressive disorder and schizophrenia. Its PNV-001 program pursues a novel therapeutic mechanism for depression, while PNV-002 targets an emerging mechanism for schizophrenia. ProNovo combines research into genetic susceptibility, disease biology, therapeutic mechanisms and prognostic biomarkers to identify and develop drug candidates for patients whose needs are not met by current psychiatric treatments. Founded by researchers and drug-development executives with experience in molecular neurotherapeutics, CNS research and small-molecule development, it is advancing its pipeline toward clinical testing. The company’s candidates remain in preclinical development.

Chief financial officer at NewVale Capital. Previously a director at CFO Fund Services, later acquired by SS&C, she managed accounting, tax and investor reporting for venture and private-equity funds. She began as a PwC auditor and holds accounting and MBA degrees from the University of Denver.

Cambridge, Massachusetts neuroscience technology company providing functional MRI services, analysis software and brain-circuit insights for drug and device developers. Its cloud platform processes fMRI scans using specialized acquisition and artifact-correction methods to measure brain activity and connectivity across patients, scanners and clinical sites. It produces Brain Insight Reports and biomarkers that help researchers characterize disease subtypes, measure treatment effects and assess which neural circuits a therapy affects. Initial applications include mood and anxiety disorders and neurodegenerative disease. Founded by physician-scientists with psychiatric neuroimaging expertise, Ceretype also develops future clinical decision-support applications, which remain under development.

Apuleyo Yanez is a research associate at Modulo Bio, as confirmed by its current named staff roster and original portrait. The biotechnology company studies the neuroimmune system using stem-cell models, neurobiology, multiomics and machine learning to develop neuroprotective therapeutic approaches.

Brent Wilkinson, PhD, is a scientist at Modulo Bio according to the company’s current public team. Modulo’s interdisciplinary research programme combines neurobiology, stem-cell engineering and computational analysis to identify drugs that modulate microglia and protect neurons in neurological disease.

David Silbersweig is published by Samphire Neuroscience as Prof David Silbersweig, MD Harvard, Brigham & Women’s Head of NeuroPsych. The company lists this affiliation within its scientific-adviser and key-collaborator group, not its statutory board.

Hannah Zheng is a senior research associate at Modulo Bio according to its current public team. Her own February2025 post confirms the company’s USD500K ALS Association grant supporting IND-enabling studies of its CSF1R inhibitor. The grant is company research funding rather than a personal financial investment.

Joseph (Joe) Wagner, PhD, is Modulo Bio’s chief development officer, announced June3,2025 and confirmed in its current team. He has more than25years of biotechnology experience and previously led R&D, software engineering and data science as chief scientific officer at Notable Labs. Earlier executive roles included BriaCell Therapeutics and OncoCyte. His experience covers therapeutic development and precision medicine across neurology, oncology and other disease areas.

Justin Ichida advises Spinogenix on science. His research at USC combines stem-cell models, cellular reprogramming and genetics to study ALS, frontotemporal dementia and potential neurodegenerative-disease therapies. He also co-founded Modulo Bio. Justin Ichida is listed among Synapticure’s scientific and strategic advisers. The issuer publishes the professional affiliation John Douglas French Foundation Endowed Professor of Stem Cell Biology and Regenerative Medicine, University of Southern California. This outside title is retained as a source-qualified professional description rather than Synapticure operating employment. Additional career details and dates are not disclosed in this directory.

Karen Sachs, PhD, is director of computational biology at Modulo Bio, as named in the company’s current public team. The company combines single-cell multiomics and machine learning with experimental neuroimmune models to identify biomarkers, biological relationships and therapeutic targets for neurological diseases.

Mark Corrigan is a Wave director and strategic advisor to Ceretype Neuromedicine. He co-founded Tremeau Pharmaceuticals and previously led Correvio and held executive positions at Zalicus, Sepracor and Pharmacia. Board-certified in psychiatry and neurology, he earned his undergraduate and medical degrees at the University of Virginia and trained at Maine Medical Center and Cornell.

Mike (Michael) Horowitz is CEO and co-founder of Modulo Bio. The company’s own launch statement describes his personal motivation after witnessing a close friend’s mother develop frontotemporal dementia. He leads a biotechnology company combining patient-derived neuroimmune models with software, automation and AI to discover drugs that reprogram microglia. The legal issuer’s SEC filing uses Michael Horowitz for this same executive.

Nina Draeger, PhD, is a senior scientist at Modulo Bio according to its current published team. She is a biochemist with research interests in neurodegeneration. Modulo’s discovery programme integrates stem-cell neuroimmune models, neurobiology and computational analysis to develop therapeutic approaches for neurological diseases.

Ryan Lim, PhD, is Modulo Bio’s director of biology and principal investigator on its ADDF-supported CSF1R inhibitor programme. His own funding announcement describes preclinical development, biomarker validation and advancement toward clinical studies for ALS and frontotemporal dementia. The company’s current published team independently confirms his leadership position.

Scott Patterson is Modulo Bio’s CTO and co-founder. The company’s launch biography identifies earlier service as Vice President of Engineering at Counsyl. Its discovery platform integrates software, automation and AI with stem-cell biology to map the neuroimmune system. The November2024 legal issuer filing names Alexander Scott Patterson, anchoring the same founder identity.

Steven Schaffert, PhD, is Modulo Bio’s principal data scientist according to its current published team. The company’s drug-discovery platform uses computational analysis, machine learning and experimental neurobiology to understand microglial cell states and therapeutic opportunities in neurodegenerative disease.

Founder of DW Fritz Automation, which Rapta's June 2025 financing announcement identifies as acquired by Sandvik in 2021. Named personal investor in Rapta's seed round.

Former Partner of Sequoia Capital, according to Rapta's June 2025 issuer financing announcement. Named personal investor in Rapta's seed round.

Rapta develops industrial AI and computer-vision systems for manufacturing guidance, inspection, quality assurance and production traceability. Its platform connects engineering, production and quality workflows and supports on-premises and air-gapped deployment for precision manufacturers, including aerospace, defense and medical-device businesses. Rapta is based in Lake Oswego, Oregon, and announced an East Coast headquarters in Cocoa Beach, Florida, in 2025. Its public team lists eight executives and five board roles, including founders Aaron J Brown, Matthew D Thornton and Matthias Daue. The company announced a $2.7 million seed round in June 2025 and an $8 million financing co-led by Voyager Capital and Access Venture Partners in September 2026. The September SEC filing reports a different equity-sold amount of $10,835,253, without explaining its relationship to the announced $8 million; it is retained as a disclosure rather than another financing. Rapta also received a $50,000 Space Florida Accelerating Innovation Award in June 2025 and was awarded $110,500 in investment commitments at the October 2025 Bend Venture Conference. Award terms and final disbursement are not independently established.

New York venture capital firm founded in 2019 that finances and helps build companies translating neuroscience, technology and data into treatments and services for patients. Its precision neuromedicine focus includes neuropsychiatric therapeutics, psychedelic medicine, mental-health care and enabling technologies. JLS backs drug developers and companies providing tools or infrastructure for neurological and psychiatric care, and supports their growth and strategic partnerships through its investment team and scientific, clinical and policy advisers.

Norwalk, Connecticut venture capital firm investing globally in biotechnology companies and platforms that aim to prevent or treat age-related disease and extend healthy lifespan. It focuses on pre-seed, seed and Series A investments and supports companies through later financing rounds. Its areas include cognitive and sensory decline, neurodegeneration, neuroinflammation, immune aging, metabolic and mitochondrial dysfunction, fibrosis and cellular senescence. It backs approaches such as small molecules, biologics, gene therapy, reprogramming technologies, drug delivery and AI-enabled drug discovery, pairing capital with scientific expertise and academic, biotech and financial networks.

Somerville, Massachusetts preclinical biotechnology company developing small-molecule treatments for neurodegenerative diseases by studying cell-to-cell communication in the brain. Its C-to-C Engine, also described as the CONNECT discovery platform, maps interactions among cells to identify signaling pathways involved in neuroinflammation, neurodegeneration and synaptic loss. Its lead program inhibits EphB3, a receptor tyrosine kinase involved in interactions between microglia and astrocytes, with the aim of preserving and repairing synapses and protecting cognitive function. The program is undergoing IND-enabling development. The company combines neuroimmunology, computational biology and cellular interaction mapping to discover therapeutic targets; its drugs remain investigational.

Bill Yelle is published by Mass General Brigham Ventures as Alumni Entrepreneur in Residence (historical affiliation; exact dates unpublished). The same source identifies the professional designation FireCyte Therapeutics, Founding CEO. Further career details and exact affiliation dates are not published in this source.

Dementia Discovery Fund venture partner, also known as James B. Summers; former AbbVie neuroscience research vice president and biotechnology director and scientific adviser.

Meredith Fisher is a Partner at Mass General Brigham Ventures, working on early company development and investment. Her published biography lists board service at BraveBio, ClarisBio, CrossTalk, Falcon Bio, Sena and Violet, with a co-founder and chief-executive affiliation at Violet. It separately identifies observer positions at Altido, Mediar and Monimoi.

Partner and co-lead of Dementia Discovery Fund, joining SV in 2026 after leading Takeda Ventures; Montara Therapeutics board member.

Delray Beach, Florida clinical-stage biotechnology company developing drug treatments for persistent loss of smell and the resulting impairment of perceived flavor. Its lead investigational therapy CYR-064 is an intranasal theophylline formulation delivered as a targeted soft-mist spray; as a phosphodiesterase inhibitor it is designed to increase olfactory neuron excitability and restore smell function after viral infections. The company reported Phase II FLAVOR results in February 2026, including achievement of the primary safety endpoint and prespecified secondary smell-function endpoints, and plans Phase III development. Cyrano also explores applications in Parkinson’s disease, where smell impairment can be an early symptom. Its therapies remain investigational.

Irvine, California biotechnology company developing cell-free, stem cell-derived biologics for age-related muscle loss, metabolic dysfunction and immune dysregulation. Its lead investigational product IMM01-STEM contains a mixture of regenerative and immunomodulatory factors secreted by partially differentiated stem cells, designed to influence multiple cellular signaling pathways without administering live cells. The company is testing the product in Phase II programs for older adults with sarcopenia and obesity-related muscle weakness. In 2026 it also licensed IMM02-KORA from Toray for dyskinesia associated with Parkinson’s disease, obtaining development and commercialization rights in the US, Canada, EU and EFTA and submitting an IND for Phase I development. Both programs remain investigational.